Abstract:It has been proposed that inhaled E-prostanoid 4 (EP4)-receptor agonists could represent a new class of bronchodilators for the treatment of asthma that are as effective as β 2-adrenoceptor agonists. However, the genomic impact of such drugs is unknown despite being potentially deleterious to respiratory health. Herein, we used mRNA-seq to compare the transcriptomic responses produced by 2-[3-[(1R,2S,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-[2-(methoxymethyl)phenyl]pent-1-enyl]-5-oxo-cyclopentyl]sulphanylpropylsulphanyl] acetic acid (ONO-AE1-329; an EP4-receptor agonist) and vilanterol (a β 2-adrenoceptor agonist) in BEAS-2B human airway epithelial cells. We also determined if an increase in cAMP mediated by different G protein-coupled receptors (GPCRs) promoted distinct transcriptional signatures by expanding this inquiry to include the adenosine A2B- and I-prostanoid receptor agonists, 2-[[6-amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide (Bay60-6583) and taprostene, respectively. Maximally-effective concentrations of ONO-AE1-329 and vilanterol significantly regulated (q ≤ 0.05; ≥1.5-/≤0.67-fold) 232 and 320 genes, respectively of which 217 were shared. Spearman analysis showed these gene expression changes to be highly rank order correlated, indicating that the functional overlap between the two interventions should be considerable. Unexpectedly, the genomic effects of ONO-AE1-329, vilanterol, Bay 60-6583, and taprostene were also highly rank order correlated. This finding suggests that cAMP generated by any GPCR would initiate the same transcriptional program. Nevertheless, relative to vilanterol, ONO-AE1-329 typically behaved as a partial agonist that varied across transcripts. These data indicate that each ONO-AE1-329-regulated gene differs in sensitivity to cAMP and is defined by a unique receptor occupancy-response relationship. Moreover, if this relatively modest genomic response in BEAS-2B cells is retained in vivo, then inhaled EP4-receptor agonists could represent an alternative, and possibly safer, class of bronchodilators. SIGNIFICANCE STATEMENT: The genomic consequences of β 2-adrenoceptor agonists in asthma are often overlooked despite being potentially harmful to lung health. We determined that ONO-AE1-329, an EP4-receptor agonist and effective bronchodilator, produced gene expression changes in BEAS-2B cells that were typically modest relative to the β 2-adrenoceptor agonist vilanterol. Furthermore, ONO-AE1-329 behaved as a partial agonist that varied across transcripts. If this genomic activity is reproduced in vivo, then EP4-receptor agonists could represent an alternative, and possibly safer, class of bronchodilators.

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.

Discovery and Identification of Novel 5-Hydroxy-4 H -benzo[1,4]oxazin-3-one Derivatives as Potent β 2 -Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

[Design, Synthesis and Antiasthmatic Activities of NO-donating Seratrodast Derivatives].

Discovery of Β-Arrestin-biased Β2-Adrenoceptor Agonists from 2-Amino-2-phenylethanol Derivatives

Design and synthesis of 2-(2,2-diarylethyl)-cyclamine derivatives as M3 receptor antagonists and functional evaluation on COPD

Discovery of a Highly Selective β 2 -Adrenoceptor Agonist with a 2-Amino-2-phenylethanol Scaffold as an Oral Antiasthmatic Agent

Recent Advances in β 2 -Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure

Recent progress in the development of β2 adrenergic receptor agonists: a patent review (2015-2020)

New promising agents against COPD and asthma among the amides of 1-oxo-3-phenyl-isochroman-6-carboxylic acid

( S )- N -Benzyl-1-phenyl-3,4-dihydroisoqunoline-2(1 H )-carboxamide Derivatives, Multi-Target Inhibitors of Monoamine Oxidase and Cholinesterase: Design, Synthesis, and Biological Activity.

Molecular hybridization yields triazole bronchodilators for the treatment of COPD

The design, synthesis and α7 nicotinic acetylcholine receptors positive allosteric modulative evaluation of 3H-quinazolin-4-one derivatives

Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐chloroquinazoline As Potential EGFR‐TK Inhibitors

A New Series of Gs‐ and Β‐arrestin‐biased Β2‐adrenoceptor Agonists

Comparison of the Genomic Activity of an EP4-Receptor and β2-Adrenoceptor Agonist in BEAS-2B Human Bronchial Epithelial Cells: In Search of Compartmentalized, cAMP-Dependent Gene Expression

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

A novel quinoline with airway relaxant effects and anti-inflammatory properties

β2-adrenergic receptor affinity chromatography with an interaction force analysis model: A method for analysis of active compounds targeting β2-adrenergic receptor

Discovery of Biphenyl Piperazines As Novel and Long Acting Muscarinic Acetylcholine Receptor Antagonists